Northwest Biotherapeutics completed the acquisition of Advent BioServices.

Northwest Biotherapeutics, a biotechnology company specializing in personalized immune therapies, completed the acquisition of Advent BioServices, a UK-based contract development and manufacturing organization. "We are excited to have completed the necessary conditions for closing the acquisition of Advent, and to be moving into position for potential significant scale-up. We believe this integration can also help accelerate development of additional applications and next-generation versions of our technologies, applying the combined expertise and the large portfolio of intellectual property that we have amassed. We believe this represents important progress in building a dominant franchise," Linda Powers, Northwest Biotherapeutics CEO.